FCRLB/FCRY Antibody (OTI5H6)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-45639
![Western Blot: FCRLB/FCRY Antibody (OTI5H6) [NBP2-45639]](https://resources.bio-techne.com/images/products/FCRLB-FCRY-Antibody-OTI5H6-Western-Blot-NBP2-45639-img0001.jpg "Western Blot: FCRLB/FCRY Antibody (OTI5H6) [NBP2-45639]")
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Rat
Applications
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # OTI5H6
Concentration
1 mg/ml
Product Specifications
Immunogen
Human recombinant protein fragment corresponding to amino acids 202-426 of human FCRLB(NP_001002901) produced in E.coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Scientific Data Images for FCRLB/FCRY Antibody (OTI5H6)
Western Blot: FCRLB/FCRY Antibody (OTI5H6) [NBP2-45639]
Western Blot: FCRLB/FCRY Antibody (OTI5H6) [NBP2-45639] - HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY FCRLB (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-FCRLB.Applications for FCRLB/FCRY Antibody (OTI5H6)
Application
Recommended Usage
Western Blot
1:2000
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS (pH 7.3), 1.0% BSA and 50% Glycerol
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: FCRLB/FCRY
Long Name
Fc Receptor-like B
Alternate Names
FcRL2, FCRLM2, FCRLY, FCRY, FREB-2
Gene Symbol
FCRLB
Additional FCRLB/FCRY Products
Product Documents for FCRLB/FCRY Antibody (OTI5H6)
Product Specific Notices for FCRLB/FCRY Antibody (OTI5H6)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...